Full Text
Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondilytis- A Cost Per Responder Analysis at 52 Weeks from a Moroccan Perspective

Abstract

Authors

A Kooli P Gunda J Toumi E Nikoglou SM Jugl

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×